Latest news with #ClarityPharmaceuticalsLtd.
Business Insider
19-06-2025
- Business
- Business Insider
Bell Potter Remains a Buy on Clarity Pharmaceuticals Ltd. (CU6)
Bell Potter analyst John Hester maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report) today and set a price target of A$4.90. The company's shares opened today at A$2.18. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 4.3% and a 46.74% success rate on recommended stocks. Clarity Pharmaceuticals Ltd. has an analyst consensus of Strong Buy, with a price target consensus of A$6.15, a 182.11% upside from current levels. In a report released on June 15, Wilsons also maintained a Buy rating on the stock with a A$8.25 price target.
Business Insider
17-06-2025
- Business
- Business Insider
Wilsons Sticks to Their Buy Rating for Clarity Pharmaceuticals Ltd. (CU6)
Wilsons analyst Shane Storey maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report) on June 15 and set a price target of A$8.25. The company's shares opened today at A$2.30. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Storey is a 4-star analyst with an average return of 7.3% and a 48.19% success rate. Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Monash IVF Group Ltd, and EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh. Currently, the analyst consensus on Clarity Pharmaceuticals Ltd. is a Strong Buy with an average price target of A$6.15, representing a 167.39% upside. In a report released on June 10, Bell Potter also maintained a Buy rating on the stock with a A$4.90 price target. The company has a one-year high of A$8.98 and a one-year low of A$1.43. Currently, Clarity Pharmaceuticals Ltd. has an average volume of 2.95M.
Business Insider
11-06-2025
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for Clarity Pharmaceuticals Ltd. (CU6)
Bell Potter analyst John Hester maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report) today and set a price target of A$4.90. The company's shares closed today at A$2.39. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hester is a 4-star analyst with an average return of 7.2% and a 50.00% success rate. Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Polynovo , and Mesoblast Limited. Currently, the analyst consensus on Clarity Pharmaceuticals Ltd. is a Strong Buy with an average price target of A$6.22, representing a 160.25% upside. In a report released on June 5, Canaccord Genuity also maintained a Buy rating on the stock with a A$6.74 price target.
Business Insider
09-05-2025
- Business
- Business Insider
Clarity Pharmaceuticals Ltd. (CU6) Receives a Buy from Bell Potter
In a report released today, John Hester from Bell Potter maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report), with a price target of A$5.20. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 7.4% and a 51.76% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clarity Pharmaceuticals Ltd. with a A$6.22 average price target. The company has a one-year high of A$8.98 and a one-year low of A$1.43. Currently, Clarity Pharmaceuticals Ltd. has an average volume of 2.56M.
